


## Joint Research Project on *in vivo* CAR-T Therapy Conducted by The University of Tokyo and Yamaguchi University, Collaborative Partners of Noile-Immune, Awarded AMED FY2026 “Project for Promotion of Cancer Research and Therapeutic Evolution”

Noile-Immune Biotech Inc. (hereinafter “the Company”) hereby announces that a joint research project (the “Project”) on *in vivo* CAR-T therapy, a novel therapeutic approach for cancer, jointly proposed by its collaborative partners, The University of Tokyo and Yamaguchi University, has been awarded funding under the FY2026 “Project for Promotion of Cancer Research and Therapeutic Evolution” of the Japan Agency for Medical Research and Development (AMED). The Company’s collaborative research with The University of Tokyo and Yamaguchi University includes research activities related to the *in vivo* CAR-T technology that is the subject of this Project.

|                        |  |
|------------------------|--|
| Project Title          | Study of clinically translatable <i>in vivo</i> CAR-T therapy using targeted mRNA micelles   |
| Grant Period           | June 2026 – End of FY2028 (up to 3 fiscal years)   |
| Annual Grant Amount    | Up to 17 million yen/year  |
| Principal Investigator | Cabral Horacio, Ph.D. (Professor, Department of Bioengineering, Graduate School of Engineering, The University of Tokyo)                   |
| Co-Investigator        | Yukimi Sakoda, M.D., Ph.D. (Associate Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine)               |
| AMED Website           | <a href="https://www.amed.go.jp/koubo/03001/02/C_00002.html">https://www.amed.go.jp/koubo/03001/02/C_00002.html</a> (Japanese version URL) |

*In vivo* CAR-T technology represents a next-generation immunotherapy that differs from conventional CAR-T therapy, which involves *ex vivo* manufacturing and administration of CAR-T cells. Instead, it enables the direct generation of CAR-T cells *in vivo* by delivering genes into T cells within the body, without the need for *ex vivo* cell culture or genetic manipulation, thereby allowing them to attack cancer (see figure below). In recent years, research and development of *in vivo* CAR-T technology have been rapidly advancing worldwide, attracting strong interest from global pharmaceutical companies.



The Company's proprietary PRIME technology, which enhances CAR-T cell function, is compatible with *in vivo* CAR-T approaches. Through the execution of this Project, further advancement of the Company's research and development in next-generation immuno-cell therapies is expected, with the potential to contribute to long-term enhancement of corporate value. Furthermore, Associate Professor Yukimi Sakoda of Yamaguchi University, a co-investigator of this Project, serves as a scientific advisor to the Company.

The impact of this matter on the Company's financial results for the fiscal year ending December 2026 is currently under evaluation. Should any matters requiring disclosure arise, the Company will promptly provide an update.

### **【Noile-Immune Biotech Inc.】**

Noile-Immune Biotech Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.

For more information, please visit <https://www.noile-immune.com/en.html>.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

[pr@noile-immune.com](mailto:pr@noile-immune.com)